Psychosis

• Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review (30 Sep 2024)
  
• The therapeutic role of Cannabidiol in mental health: a systematic review (24 Sep 2024)
  
• Overbaked: assessing and predicting acute adverse reactions to Cannabis (24 Sep 2024)
  
• Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis (24 Sep 2024)
  
• Cannabis and Psychosis: A Review of the Risk Factors Involved (17 Sep 2024)
  
• Cannabis use and nonuse in patients with first-episode psychosis: A systematic review and meta-analysis of studies comparing neurocognitive functioning (16 Sep 2024)
  
• Associations Between Prenatal Cannabis Exposure and Childhood Outcomes (16 Sep 2024)
  
• Association of early onset of cannabis, cigarette, other drug use and schizophrenia or psychosis (16 Sep 2024)
  
• Adverse events following cannabis for medical use in Tuscany: An analysis of the Italian Phytovigilance database (16 Sep 2024)
  
• Clinical and cognitive outcomes in first-episode psychosis: focus on the interplay between cannabis use and genetic variability in endocannabinoid receptors (03 Sep 2024)
  
• DNA methylation at cannabinoid type 1 and dopamine D2 receptor genes in saliva samples of psychotic subjects: Is there an effect of Cannabis use? (02 Sep 2024)
  
• Potential Role of Cannabinoid Type 2 Receptors in Neuropsychiatric and Neurodegenerative Disorders (25 Aug 2024)
  
• Changes in Expression of DNA-Methyltransferase and Cannabinoid Receptor mRNAs in Blood Lymphocytes After Acute Cannabis Smoking (25 Aug 2024)
  
• Cannabinoid type-2 receptors: An emerging target for regulating schizophrenia-relevant brain circuits (25 Aug 2024)
  
• Prenatal Cannabinoid Exposure: Emerging Evidence of Physiological and Neuropsychiatric Abnormalities (20 Aug 2024)
  
• Peripheral Endogenous Cannabinoid Levels Are Increased in Schizophrenia Patients Evaluated in a Psychiatric Emergency Setting (20 Aug 2024)
  
• Neural Substrates of Incidental Associations and Mediated Learning: The Role of Cannabinoid Receptors (20 Aug 2024)
  
• Synthetic and Non-synthetic Cannabinoid Drugs and Their Adverse Effects-A Review From Public Health Prospective (18 Aug 2024)
  
• Clinical characteristics of synthetic cannabinoid-induced psychosis in relation to schizophrenia: a single-center cross-sectional analysis of concurrently hospitalized patients (18 Aug 2024)
  
• Cannabidiol, among Other Cannabinoid Drugs, Modulates Prepulse Inhibition of Startle in the SHR Animal Model: Implications for Schizophrenia Pharmacotherapy (18 Aug 2024)
  
• First-Episode of Synthetic Cannabinoid-Induced Psychosis in a Young Adult, Successfully Managed with Hospitalization and Risperidone (12 Aug 2024)
  
• Editorial: The Endocannabinoid System: Filling the Translational Gap Between Neuroscience and Psychiatry (05 Sep 2022)
  
• The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study (07 Aug 2022)
  
• The Autism–Psychosis Continuum Conundrum: Exploring the Role of the Endocannabinoid System (31 Jul 2022)
  
• The use and effects of synthetic cannabinoid receptor agonists by New South Wales cannabis treatment clients - Journal of Cannabis Research (26 Jul 2022)
  
• The therapeutic role of Cannabidiol in mental health: a systematic review - Journal of Cannabis Research (26 Jul 2022)
  
• Staff awareness of the use of cannabidiol (CBD): a trust-wide survey study in the UK - Journal of Cannabis Research (26 Jul 2022)
  
• Medicinal cannabis: knowledge, beliefs, and attitudes of Colombian psychiatrists - Journal of Cannabis Research (26 Jul 2022)
  
• Pioneering clinical trial to treat psychosis in Parkinson's patients using cannabidiol (18 Jul 2022)
  
• New insight into how cannabidiol takes effect in the brains of people with psychosis (18 Jul 2022)
  
• Cannabis extract helps reset brain function in psychosis (18 Jul 2022)